التفاصيل البيبلوغرافية
| العنوان: |
Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study. |
| المؤلفون: |
Kotani, Daisuke, Yoshino, Takayuki, Kotaka, Masahito, Kawazoe, Akihito, Masuishi, Toshiki, Taniguchi, Hiroya, Yamazaki, Kentaro, Yamanaka, Takeharu, Oki, Eiji, Muro, Kei, Komatsu, Yoshito, Bando, Hideaki, Satake, Hironaga, Kato, Takeshi, Tsuji, Akihito |
| المصدر: |
Investigational New Drugs; Dec2021, Vol. 39 Issue 6, p1649-1655, 7p |
| مصطلحات موضوعية: |
THERAPEUTIC use of antimetabolites, THERAPEUTIC use of antineoplastic agents, DRUG efficacy, METASTASIS, ANTINEOPLASTIC agents, IRINOTECAN, NEUTROPENIA, HEALTH outcome assessment, COLORECTAL cancer, RANDOMIZED controlled trials, CANCER patients, ANTIMETABOLITES, DESCRIPTIVE statistics, OXALIPLATIN, BEVACIZUMAB, STATISTICAL sampling, PHARMACODYNAMICS |
| مستخلص: |
Summary: Background FOLFOXIRI plus bevacizumab is the first-line treatment for metastatic colorectal cancer (mCRC) but demonstrates high neutropenia incidence among Asian patients. Hence, we conducted the randomized phase II QUATTRO-II study (ClinicalTrials.gov identifier: NCT04097444; Japan Registry of Clinical Trials identifier: jRTCs041190072) to evaluate the safety and efficacy of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) combination plus bevacizumab versus FOLFOXIRI plus bevacizumab, expecting a lower incidence of neutropenia without compromising the efficacy. Methods We investigated the recommended doses (RD) of oxaliplatin and irinotecan as a safety lead-in portion of Step 1 before initiating the randomized portion as Step 2. Four dose levels of CAPOXIRI (fixed dose of capecitabine, 1600 mg/m2; escalated/de-escalated doses of oxaliplatin and irinotecan) plus bevacizumab (7.5 mg/kg) were investigated in a 3 + 3 manner. A dose level of ≤ 2/6 of dose-limiting toxicity (DLT) cases was expected as the RD. Results In Step 1, we included nine patients (three and six in levels 0 and + 1, respectively). Level 0 (irinotecan, 200 mg/m2; oxaliplatin, 100 mg/m2) did not demonstrate DLTs. In level + 1 (irinotecan, 200 mg/m2; oxaliplatin, 130 mg/m2), although one patient experienced grade 4 febrile neutropenia, no further safety concerns were observed. As a preliminary efficacy result, the objective response rate in all nine patients was 89 % (100 and 83 % in levels 0 and + 1, respectively). Conclusions The RD of CAPOXIRI plus bevacizumab was 200, 130, and 1600 mg/m2 for irinotecan, oxaliplatin, and capecitabine, respectively, and 7.5 mg/kg for bevacizumab. The randomized portion is still ongoing. [ABSTRACT FROM AUTHOR] |
|
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder